2021
Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States
Wilson LE, Spees L, Pritchard J, Greiner MA, Scales CD, Baggett CD, Kaye D, George DJ, Zhang T, Wheeler SB, Dinan MA. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States. Kidney Cancer 2021, 5: 115-127. PMID: 34632169, PMCID: PMC8474520, DOI: 10.3233/kca-210119.Peer-Reviewed Original ResearchOral anticancer agentsMetastatic RCCPatient characteristicsMetastatic renal cell carcinomaPocket costsFirst oral therapySEER-Medicare analysisRepresentative patient populationRenal cell carcinomaAnticancer agentsPrescription drug coverageRace/ethnicityMRCC diagnosisMost patientsOral therapyUnmarried patientsCell carcinomaPatient populationAdvanced ageInclusion criteriaPatientsDrug coverageAge 65Medicare Part D prescription drug coverageSocioeconomic disparities
2020
Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States.
Wilson L, Spees L, Pritchard J, Greiner M, Scales C, Baggett C, Kaye D, George D, Zhang T, Wheeler S, Dinan M. Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States. Journal Of Clinical Oncology 2020, 38: 106-106. DOI: 10.1200/jco.2020.38.29_suppl.106.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaPatient characteristicsCell carcinomaManagement of mRCCSEER-Medicare patientsMultivariable-adjusted modelsMajority of patientsPatient-level characteristicsAnticancer agentsMedicare Part D benefitPart D benefitSurvival persistCertain comorbiditiesElderly patientsMultivariable adjustmentMarried patientsMetastatic diagnosisRace/ethnicity categoriesAdvanced ageInclusion criteriaHispanic ethnicityPatientsPocket spending